Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease

[1]  J. Alió,et al.  Quantification of Growth Factors and Fibronectin in Diverse Preparations of Platelet-Rich Plasma for the Treatment of Ocular Surface Disorders (E-PRP) , 2020, Translational vision science & technology.

[2]  Joong Il Kim,et al.  Effect of Storage Conditions and Activation on Growth Factor Concentration in Platelet‐Rich Plasma , 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[3]  Brendan H. Lee,et al.  Effects of Aspirin on Growth Factor Release From Freshly Isolated Leukocyte-Rich Platelet-Rich Plasma in Healthy Men: A Prospective Fixed-Sequence Controlled Laboratory Study , 2019, The American journal of sports medicine.

[4]  S. Hakim,et al.  Impact of incubation method on the release of growth factors in non-Ca2+-activated PRP, Ca2+-activated PRP, PRF and A-PRF. , 2019, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[5]  D. Piñero,et al.  Efficacy and safety of treatment of hyposecretory dry eye with platelet‐rich plasma , 2018, Acta ophthalmologica.

[6]  Tayyeba K. Ali,et al.  Use of Autologous Serum Tears for the Treatment of Ocular Surface Disease From Patients With Systemic Autoimmune Diseases. , 2018, American journal of ophthalmology.

[7]  Marina Viegas Moura Rezende Ribeiro,et al.  The use of platelet rich-plasma in Ophthalmology: a literature review , 2017 .

[8]  J. Alió,et al.  Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study , 2017, Ophthalmology and Therapy.

[9]  D. Schaumberg,et al.  TFOS DEWS II Epidemiology Report. , 2017, The ocular surface.

[10]  R. Dana,et al.  TFOS DEWS II Management and Therapy Report. , 2017, The ocular surface.

[11]  V. Perez,et al.  Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies , 2015, Acta ophthalmologica.

[12]  G. Orive,et al.  Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. , 2015, Experimental eye research.

[13]  R. Davis,et al.  The association between dry eye disease and depression and anxiety in a large population-based study. , 2015, American journal of ophthalmology.

[14]  G. Verreck,et al.  Preclinical and Clinical Studies , 2015 .

[15]  H. Datta,et al.  Comparative role of 20% cord blood serum and 20% autologous serum in dry eye associated with Hansen's disease: a tear proteomic study , 2014, British Journal of Ophthalmology.

[16]  R. Topolski,et al.  Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. , 2014, Military medicine.

[17]  K. Tsubota,et al.  Dry-eye screening by using a functional visual acuity measurement system: the Osaka Study. , 2014, Investigative ophthalmology & visual science.

[18]  A. Celebi,et al.  The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.

[19]  G. Orive,et al.  Biological Stability of Plasma Rich in Growth Factors Eye Drops After Storage of 3 Months , 2013, Cornea.

[20]  W. Knez,et al.  Exercise and the platelet activator calcium chloride both influence the growth factor content of platelet-rich plasma (PRP): overlooked biochemical factors that could influence PRP treatment , 2013, British Journal of Sports Medicine.

[21]  H. Kim,et al.  Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis , 2012, Japanese Journal of Ophthalmology.

[22]  P. Lertrit,et al.  Stability of Epitheliotrophic Factors in Autologous Serum Eye Drops from Chronic Stevens-Johnson Syndrome Dry Eye Compared to Non-autoimmune Dry Eye , 2011, Current eye research.

[23]  A. Behrens,et al.  Autologous serum for ocular surface diseases. , 2008, Arquivos brasileiros de oftalmologia.

[24]  J. Bradley,et al.  Serum growth factor analysis in dry eye syndrome , 2008, Clinical & experimental ophthalmology.

[25]  J. Alió,et al.  Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma , 2007, Ophthalmic Research.

[26]  A. Bron,et al.  Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests , 2003, Cornea.

[27]  S. Pieh,et al.  Effect of tenascin and fibronectin on the migration of human corneal fibroblasts , 2003, Journal of cataract and refractive surgery.

[28]  Y. Tano,et al.  The effect of TGF-beta1 on differential gene expression profiles in human corneal epithelium studied by cDNA expression array. , 2001, Investigative ophthalmology & visual science.

[29]  R. Mohan,et al.  Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea. , 1999, Investigative ophthalmology & visual science.

[30]  P. Khaw,et al.  EFFECTS OF GROWTH FACTORS ON CORNEAL WOUND HEALING , 1992, Acta ophthalmologica. Supplement.

[31]  M. Nakamura,et al.  Differential modes of action of fibronectin and epidermal growth factor on rabbit corneal epithelial migration , 1990, Journal of cellular physiology.

[32]  S. Nakagawa,et al.  Fibronectin enhancement of corneal epithelial wound healing of rabbits in vivo. , 1984, Archives of ophthalmology.

[33]  Mitchell P. Weikert,et al.  Autologous Serum-Based Eye Drops for Treatment of Ocular Surface Disease: A Report by the American Academy of Ophthalmology. , 2019, Ophthalmology.

[34]  Martyn Shuttleworth,et al.  What is a NOT a Literature Review ? , 2018 .

[35]  U. Mazurek,et al.  Quantitative analysis of transforming growth factor beta isoforms mRNA in the human corneal epithelium. , 2008, Folia biologica.